Combination strategies to maximize the benefits of cancer immunotherapy.
Combination strategies to maximize the benefits of cancer immunotherapy.
复制标题
DOI：
10.1186/s13045-021-01164-5
复制
发表时间：
2021-09-27
影响因子：
28.5
通讯作者：
Pan CX
中科院分区：
文献类型：
--
作者：
Zhu S;Zhang T;Zheng L;Liu H;Song W;Liu D;Li Z;Pan CX
免疫检查点阻断（ICB）和过继细胞疗法（ACT）等免疫疗法已经彻底改变了癌症治疗，特别是在那些被认为无法治愈的患者中。然而，对单药免疫疗法的原发性和继发性耐药往往导致治疗失败，只有少数患者经历了长期的益处。这篇综述文章将讨论癌症免疫反应和免疫治疗抵抗机制之间的关系。它还将提供关于联合治疗的最新临床状态的全面综述（例如，免疫疗法与化疗、放射疗法和靶向疗法），并讨论美国食品和药物管理局批准的联合疗法。它将提供针对细胞因子和其他可溶性免疫调节因子，ACT，病毒疗法，先天免疫调节剂和癌症疫苗，以及利用替代免疫靶点和其他治疗方式的联合疗法的概述。最后，本综述将包括由美籍华人血液病学家和肿瘤学家网络（CAHON），中国国家药品监督管理局（NMPA）和清华大学医学院共同组织的2020年中国免疫肿瘤学研讨会的启发性见解。
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will discuss the relationship between cancer immune response and mechanisms of resistance to immunotherapy. It will also provide a comprehensive review on the latest clinical status of combination therapies (e.g., immunotherapy with chemotherapy, radiation therapy and targeted therapy), and discuss combination therapies approved by the US Food and Drug Administration. It will provide an overview of therapies targeting cytokines and other soluble immunoregulatory factors, ACT, virotherapy, innate immune modifiers and cancer vaccines, as well as combination therapies that exploit alternative immune targets and other therapeutic modalities. Finally, this review will include the stimulating insights from the 2020 China Immuno-Oncology Workshop co-organized by the Chinese American Hematologist and Oncologist Network (CAHON), the China National Medical Product Administration (NMPA) and Tsinghua University School of Medicine.
登录
查看更多内容
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
64.5
作者：
André P;Denis C;Soulas C;Bourbon-Caillet C;Lopez J;Arnoux T;Bléry M;Bonnafous C;Gauthier L;Morel A;Rossi B;Remark R;Breso V;Bonnet E;Habif G;Guia S;Lalanne AI;Hoffmann C;Lantz O;Fayette J;Boyer-Chammard A;Zerbib R;Dodion P;Ghadially H;Jure-Kunkel M;Morel Y;Herbst R;Narni-Mancinelli E;Cohen RB;Vivier E
通讯作者：
Vivier E
影响因子：
28.5
作者：
Basher, Fahmin;Dhar, Payal;Wu, Jennifer D.
通讯作者：
Wu, Jennifer D.
影响因子：
5.3
作者：
BRABLETZ, T;PFEUFFER, I;SERFLING, E
通讯作者：
SERFLING, E
影响因子：
20.3
作者：
Braig, Friederike;Brandt, Anna;Binder, Mascha
通讯作者：
Binder, Mascha